
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

ENANTA PHARMACEUTICALS INC	
(Name of Issuer)	
COMMON STOCK, Par Value \$0.01 Per Share	
(Title of Class of Securities)	
29251M106	
(CUSIP Number)	
02/22/2024	
(Date of Event Which Requires Filing of this Statement)	
Check the appropriate box to designate the rule pursuant to which this Schedule is filed Rule 13d-1(b) Rule 13d-1(c)	:
Rule 13d-1(d)	

SCHEDULE 13G

CUSIP No. 29251M106



Beneficially Owned by Each Reporting Person With:	Shared Voting Power 1,086,024.00 Sole Dispositive Power 0.00 Shared Dispositive Power
	1,086,024.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,086,024.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9)
	5.1 %
	Type of Reporting Person (See Instructions)
12	IA

SCHEDULE 13G

CUSIP No. 29251M106

```
Names of Reporting Persons
1
           KRENSAVAGE PARTNERS LP
           Check the appropriate box if a member of a Group (see instructions)
2
            (a)
           (b)
           Sec Use Only
3
           Citizenship or Place of Organization
4
           DELAWARE
              Sole Voting Power
              0.00
Number of
              Shared Voting Power
Shares
Beneficially
              979,910.00
Owned by
              Sole Dispositive Power
Each
Reporting
              0.00
Person
              Shared Dispositive
With:
            8 Power
              979,910.00
           Aggregate Amount Beneficially Owned by Each Reporting Person
9
           979,910.00
           Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
           Percent of class represented by amount in row (9)
11
```

```
4.6 %
            Type of Reporting Person (See Instructions)
12
            PN
```

SCHEDULE 13G

CUSIP No. 29251M106

```
Names of Reporting Persons
1
            Krensavage Partners Too, LP
            Check the appropriate box if a member of a Group (see instructions)
2
            (a)
            (b)
            Sec Use Only
3
            Citizenship or Place of Organization
            DELAWARE
               Sole Voting Power
            5
               0.00
Number of
               Shared Voting Power
Shares
Beneficially
               106,114.00
Owned by
               Sole Dispositive Power
Each
Reporting
               0.00
Person
               Shared Dispositive
With:
            8 Power
               106,114.00
            Aggregate Amount Beneficially Owned by Each Reporting Person
9
            106,114.00
            Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
            Percent of class represented by amount in row (9)
11
            0.5 %
            Type of Reporting Person (See Instructions)
12
            PN
```

SCHEDULE 13G

Item 1.

(a)

```
Name of issuer:
(a)
         ENANTA PHARMACEUTICALS INC
         Address of issuer's principal executive offices:
(b)
         500 ARSENAL STREET, WATERTOWN, MASSACHUSETTS, 02472
Item 2.
         Name of person filing:
```

(b)	(i) Krensavage Partners, LP (KP) with respect to shares of Common Stock directly owned by it. (ii) Krensavage Partners Too, LP (KPT) with respect to shares of Common Stock directly owned by it. (iii) Krensavage Asset Management LLC (KAM) with respect to shares of Common Stock beneficially owned by it. Address or principal business office or, if none, residence: 610 Fifth Avenue, Suite 301 New York, NY 10020
(c)	Citizenship:
(d)	Delaware Title of class of securities:
(e)	COMMON STOCK, Par Value \$0.01 Per Share CUSIP No.:
Item 3. (a) (b) (c) (d) (e) (f) (g) (h) (i)	29251M106 If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: ■ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); ■ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); ■ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); ■ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); ✓ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); ■ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); ■ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); ■ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); ■ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); ■ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ■ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,086,024 Percent of class:
(b) (c)	5.1% % Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote:
	1,086,024
	(iii) Sole power to dispose or to direct the disposition of:
	0
	(iv) Shared power to dispose or to direct the disposition of:
	1,086,024
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if

such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

As the discretionary investment manager of the KP and KPT LP's, KAM has the power to direct the voting and disposition of shares held by KP and KPT LP's.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Item(s) 2(a), 2(b), 2(c), 2(d) of Ownership Group - Krensavage Partners, LP (KP) and Krensavage Partners Too, LP (KPT) and Krensavage Asset Management LLC (KAM)

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Krensavage Asset Management, LLC

Signature: /s/ Paul J. Paolino

Name/Title: Chief Financial Officer & Chief Compliance

Officer

Date: 02/26/2024

KRENSAVAGE PARTNERS LP

Signature: /s/ Paul J. Paolino

Name/Title: Chief Financial Officer & Chief Compliance

Officer

Date: 02/26/2024

Krensavage Partners Too, LP

Signature: /s/ Paul J. Paolino

Name/Title: Chief Financial Officer & Chief Compliance

Officer

Date: 02/26/2024